Karo Bio AB is seeking SEK280 million (US$35.9 million) in a discounted rights issue to fund its switch from early stage discovery to clinical development. (BioWorld International)

Karo Bio AB is seeking SEK280 million (US$35.9 million) in a discounted rights issue to fund its switch from early stage discovery to clinical development. (BioWorld International)